Alecensa trial stopped early; meets primary endpoint
10 February 2016 | By Victoria White
The study showed that patients with NSCLC lived significantly longer without disease worsening when treated with Alecensa compared to crizotinib...
List view / Grid view
10 February 2016 | By Victoria White
The study showed that patients with NSCLC lived significantly longer without disease worsening when treated with Alecensa compared to crizotinib...
28 January 2016 | By Victoria White
The designation is for venetoclax in combination with HMAs for the treatment of patients with untreated AML who are ineligible to receive standard induction therapy...
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
20 January 2016 | By Victoria White
Venetoclax is an investigational small molecule designed to selectively bind and inhibit the BCL-2 protein, which plays an important role in a process called apoptosis...
13 January 2016 | By Victoria White
Results from a study demonstrate that Roche’s cardiac troponin T-high-sensitivity test shortens the time to diagnose heart attack to one hour from three hours or more...
12 January 2016 | By Victoria White
The NDA for venetoclax is for the treatment of people with chronic lymphocytic leukaemia who have received at least one prior therapy, including those with 17p deletion...
8 January 2016 | By Victoria White
Median overall survival from the updated study results was 11.4 months in people with higher levels of PD-L1 expression, and 7.9 months in the overall study population...
7 January 2016 | By Nicholas Jackson
PROGNOSIS study published in the New England Journal of Medicine reveals that an innovative Roche blood test can be used as a predictive tool for preeclampsia...
5 January 2016 | By Victoria White
IONIS-HTTRx is a Gen. 2.0+ antisense drug in development for the treatment of Huntington's disease...
14 December 2015 | By Victoria White
Alecensa (alectinib) is approved for patients whose disease has worsened after, or who could not tolerate treatment with Xalkori (crizotinib)...
1 December 2015 | By Victoria White
The novel, oral small molecule inhibitor of VAP-1 is a cell-adhesion molecule that may be effective in the treatment of inflammatory diseases...
25 November 2015 | By Victoria White
The approval is based on data that showed Cotellic plus Zelboraf helped people with previously untreated BRAF V600 mutation-positive advanced melanoma live for more than a year without their disease worsening...
17 November 2015 | By Victoria White
NICE has published final draft guidance not recommending the use of Kadcyla as a treatment for a type of advanced breast cancer because the price is too high...
13 November 2015 | By Victoria White
Tagrisso (AZD9291) is the only approved medicine indicated for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer...
13 November 2015 | By Victoria White
Roche plans to restructure its manufacturing network for small molecules to address current underutilisation as a result of its evolving portfolio...